Get the Stockscreener App
9.94
14.24%
-1.65
After Hours:
9.94
Avadel Pharmaceuticals Plc stock is traded at $9.94, with a volume of 4.24M.
It is down -14.24% in the last 24 hours and down -33.95% over the past month.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
See More
Previous Close:
$11.59
Open:
$11.3
24h Volume:
4.24M
Relative Volume:
3.63
Market Cap:
$957.83M
Revenue:
$47.56M
Net Income/Loss:
$-156.83M
P/E Ratio:
-4.7788
EPS:
-2.08
Net Cash Flow:
$-127.98M
1W Performance:
-10.85%
1M Performance:
-33.95%
6M Performance:
-36.53%
1Y Performance:
-20.67%
1-Day Range:
$9.41
$11.44
1-Week Range:
$9.41
$11.66
52-Week Range:
$9.41
$19.09
Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile
Name
Avadel Pharmaceuticals Plc
Sector
Phone
636-449-1830
Address
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN
Compare AVDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVDL
Avadel Pharmaceuticals Plc
|
9.94 | 957.83M | 47.56M | -156.83M | -127.98M | -1.83 |
|
ZTS
Zoetis Inc
|
176.94 | 79.24B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.92 | 43.58B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
HLN
Haleon Plc Adr
|
9.71 | 43.54B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.53 | 19.58B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
13.00 | 15.64B | 15.05B | -883.30M | 1.89B | -0.74 |
Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-12-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-05-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-05-24 | Reiterated | Needham | Buy |
| Mar-05-24 | Reiterated | Oppenheimer | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Nov-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-28-22 | Resumed | Craig Hallum | Buy |
| May-26-22 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jul-21-20 | Initiated | SVB Leerink | Outperform |
| Jun-30-20 | Initiated | H.C. Wainwright | Buy |
| Apr-03-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Initiated | Stifel | Buy |
| Feb-26-20 | Initiated | Piper Sandler | Overweight |
| Jan-30-20 | Initiated | Craig Hallum | Buy |
| Jun-14-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-08-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
View All
Avadel Pharmaceuticals Plc Stock (AVDL) Latest News
Avadel Pharmaceuticals sees shares drop after CCO resignation By Investing.com - Investing.com Nigeria
Avadel Pharmaceuticals announces CCO resignation - Investing.com
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Avadel Pharmaceuticals PLC (AVDL) Shares Up 3.53% on Dec 2 - GuruFocus.com
Where are the Opportunities in (AVDL) - Stock Traders Daily
The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27% - Simply Wall St
Braidwell LP Grows Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - MarketBeat
Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky (AVDL) - Seeking Alpha
Avadel Pharmaceuticals PLC (AVDL) Shares Up 3% on Nov 22 - GuruFocus.com
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Short Interest Down 7.3% in October - MarketBeat
What is HC Wainwright’s Estimate for AVDL FY2024 Earnings? - Defense World
Idiopathic Hypersomnia Treatment Market will experience - openPR
HC Wainwright Issues Pessimistic Forecast for AVDL Earnings - MarketBeat
What is Lifesci Capital's Forecast for AVDL FY2024 Earnings? - MarketBeat
What is Leerink Partnrs' Forecast for AVDL FY2024 Earnings? - MarketBeat
Avadel Pharmaceuticals plc (AVDL) Outlook: Looking Back For Insights - Stocks Register
Janus Henderson Group's Strategic Acquisition of Avadel Pharmace - GuruFocus.com
FY2025 Earnings Estimate for AVDL Issued By Leerink Partnrs - MarketBeat
Avadel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance UK
Avadel Pharmaceuticals plc (AVDL) Quarterly 10-Q Report - Quartz
Avadel shares price target cut, maintains buy on Q3 results By Investing.com - Investing.com Nigeria
Polar Capital Holdings Plc's Strategic Reduction in Avadel Pharm - GuruFocus.com
Avadel Pharmaceuticals PLC (AVDL) Shares Down 7.38% on Nov 13 - GuruFocus.com
Avadel Pharmaceuticals (NASDAQ:AVDL) Announces Earnings Results - MarketBeat
Avadel Pharmaceuticals (NASDAQ:AVDL) Stock Price Down 3.9% After Analyst Downgrade - MarketBeat
HC Wainwright Has Lowered Expectations for Avadel Pharmaceuticals (NASDAQ:AVDL) Stock Price - MarketBeat
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2024 Earnings Call Transcript - Insider Monkey
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference - The Manila Times
Avadel Pharmaceuticals to Present at Jefferies London Healthcare Conference | AVDL Stock News - StockTitan
Avadel Pharmaceuticals Reports Strong Growth with LUMRYZ - TipRanks
Avadel: Q3 Earnings Snapshot - Houston Chronicle
Avadel Pharmaceuticals PLC (AVDL) Stock Price Down 15.83% on Nov 12 - GuruFocus.com
Avadel Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Needham & Company LLC Reiterates Buy Rating for Avadel Pharmaceuticals (NASDAQ:AVDL) - MarketBeat
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Avadel's LUMRYZ Sales Surge to $50M as Patient Base Grows 44% in Q3 | AVDL Stock News - StockTitan
Avadel Pharmaceuticals PLC (AVDL) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Learn to Evaluate (AVDL) using the Charts - Stock Traders Daily
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Avadel Pharmaceuticals (AVDL) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12 - The Manila Times
Avadel Pharmaceuticals (NASDAQ:AVDL) Earns “Buy” Rating from Needham & Company LLC - Defense World
Oppenheimer Forecasts Strong Price Appreciation for Avadel Pharmaceuticals (NASDAQ:AVDL) Stock - Defense World
Avadel Pharmaceuticals’ (AVDL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Court Denies Jazz’s Challenge of Avadel’s Orphan Drug Lumryz - Sleep Review
US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle - Yahoo Finance
Loss-Making Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term - Yahoo Finance
Avadel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AVDL) - Defense World
Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ By Investing.com - Investing.com South Africa
Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap UpStill a Buy? - MarketBeat
Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ - Investing.com
Avadel Pharmaceuticals Plc Stock (AVDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):